Ensysce Biosciences Inc (NASDAQ: ENSC)’s stock price has gone decline by -10.94 in comparison to its previous close of 3.29, however, the company has experienced a 76.51% increase in its stock price over the last five trading days. accessnewswire.com reported 2025-04-24 that SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 630,376 shares of common stock of the Company originally issued in March 2025, having an exercise price of $3.24 per share. The shares of common stock issued upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No.
Is It Worth Investing in Ensysce Biosciences Inc (NASDAQ: ENSC) Right Now?
ENSC has 36-month beta value of 1.06. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ENSC is 1.62M, and currently, short sellers hold a 8.33% ratio of that float. The average trading volume of ENSC on April 29, 2025 was 1.57M shares.
ENSC’s Market Performance
ENSC stock saw a decrease of 76.51% in the past week, with a monthly decline of -6.09% and a quarterly a decrease of -59.92%. The volatility ratio for the week is 20.42%, and the volatility levels for the last 30 days are 17.22% for Ensysce Biosciences Inc (ENSC). The simple moving average for the past 20 days is 26.06% for ENSC’s stock, with a -49.97% simple moving average for the past 200 days.
ENSC Trading at -20.38% from the 50-Day Moving Average
After a stumble in the market that brought ENSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.03% of loss for the given period.
Volatility was left at 17.22%, however, over the last 30 days, the volatility rate increased by 20.42%, as shares sank -9.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.57% lower at present.
During the last 5 trading sessions, ENSC rose by +76.51%, which changed the moving average for the period of 200-days by -57.63% in comparison to the 20-day moving average, which settled at $2.32. In addition, Ensysce Biosciences Inc saw -64.00% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENSC
Current profitability levels for the company are sitting at:
- -13.8 for the present operating margin
- -0.94 for the gross margin
The net margin for Ensysce Biosciences Inc stands at -16.38. The total capital return value is set at -1.99. Equity return is now at value -471.82, with -192.33 for asset returns.
Based on Ensysce Biosciences Inc (ENSC), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -24.87. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -5.22.
Currently, EBITDA for the company is -6.73 trillion with net debt to EBITDA at 0.66. When we switch over and look at the enterprise to sales, we see a ratio of 3.32. The receivables turnover for the company is 3.93for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.42.
Conclusion
To put it simply, Ensysce Biosciences Inc (ENSC) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
